Cargando…
Genomic loss of the putative tumor suppressor gene E2A in human lymphoma
The transcription factor E2A is essential for lymphocyte development. In this study, we describe a recurrent E2A gene deletion in at least 70% of patients with Sézary syndrome (SS), a subtype of T cell lymphoma. Loss of E2A results in enhanced proliferation and cell cycle progression via derepressio...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149217/ https://www.ncbi.nlm.nih.gov/pubmed/21788410 http://dx.doi.org/10.1084/jem.20101785 |
_version_ | 1782209432567939072 |
---|---|
author | Steininger, Anne Möbs, Markus Ullmann, Reinhard Köchert, Karl Kreher, Stephan Lamprecht, Björn Anagnostopoulos, Ioannis Hummel, Michael Richter, Julia Beyer, Marc Janz, Martin Klemke, Claus-Detlev Stein, Harald Dörken, Bernd Sterry, Wolfram Schrock, Evelin Mathas, Stephan Assaf, Chalid |
author_facet | Steininger, Anne Möbs, Markus Ullmann, Reinhard Köchert, Karl Kreher, Stephan Lamprecht, Björn Anagnostopoulos, Ioannis Hummel, Michael Richter, Julia Beyer, Marc Janz, Martin Klemke, Claus-Detlev Stein, Harald Dörken, Bernd Sterry, Wolfram Schrock, Evelin Mathas, Stephan Assaf, Chalid |
author_sort | Steininger, Anne |
collection | PubMed |
description | The transcription factor E2A is essential for lymphocyte development. In this study, we describe a recurrent E2A gene deletion in at least 70% of patients with Sézary syndrome (SS), a subtype of T cell lymphoma. Loss of E2A results in enhanced proliferation and cell cycle progression via derepression of the protooncogene MYC and the cell cycle regulator CDK6. Furthermore, by examining the gene expression profile of SS cells after restoration of E2A expression, we identify several E2A-regulated genes that interfere with oncogenic signaling pathways, including the Ras pathway. Several of these genes are down-regulated or lost in primary SS tumor cells. These data demonstrate a tumor suppressor function of E2A in human lymphoid cells and could help to develop new treatment strategies for human lymphomas with altered E2A activity. |
format | Online Article Text |
id | pubmed-3149217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-31492172012-02-01 Genomic loss of the putative tumor suppressor gene E2A in human lymphoma Steininger, Anne Möbs, Markus Ullmann, Reinhard Köchert, Karl Kreher, Stephan Lamprecht, Björn Anagnostopoulos, Ioannis Hummel, Michael Richter, Julia Beyer, Marc Janz, Martin Klemke, Claus-Detlev Stein, Harald Dörken, Bernd Sterry, Wolfram Schrock, Evelin Mathas, Stephan Assaf, Chalid J Exp Med Brief Definitive Report The transcription factor E2A is essential for lymphocyte development. In this study, we describe a recurrent E2A gene deletion in at least 70% of patients with Sézary syndrome (SS), a subtype of T cell lymphoma. Loss of E2A results in enhanced proliferation and cell cycle progression via derepression of the protooncogene MYC and the cell cycle regulator CDK6. Furthermore, by examining the gene expression profile of SS cells after restoration of E2A expression, we identify several E2A-regulated genes that interfere with oncogenic signaling pathways, including the Ras pathway. Several of these genes are down-regulated or lost in primary SS tumor cells. These data demonstrate a tumor suppressor function of E2A in human lymphoid cells and could help to develop new treatment strategies for human lymphomas with altered E2A activity. The Rockefeller University Press 2011-08-01 /pmc/articles/PMC3149217/ /pubmed/21788410 http://dx.doi.org/10.1084/jem.20101785 Text en © 2011 Steininger et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/). |
spellingShingle | Brief Definitive Report Steininger, Anne Möbs, Markus Ullmann, Reinhard Köchert, Karl Kreher, Stephan Lamprecht, Björn Anagnostopoulos, Ioannis Hummel, Michael Richter, Julia Beyer, Marc Janz, Martin Klemke, Claus-Detlev Stein, Harald Dörken, Bernd Sterry, Wolfram Schrock, Evelin Mathas, Stephan Assaf, Chalid Genomic loss of the putative tumor suppressor gene E2A in human lymphoma |
title | Genomic loss of the putative tumor suppressor gene E2A in human lymphoma |
title_full | Genomic loss of the putative tumor suppressor gene E2A in human lymphoma |
title_fullStr | Genomic loss of the putative tumor suppressor gene E2A in human lymphoma |
title_full_unstemmed | Genomic loss of the putative tumor suppressor gene E2A in human lymphoma |
title_short | Genomic loss of the putative tumor suppressor gene E2A in human lymphoma |
title_sort | genomic loss of the putative tumor suppressor gene e2a in human lymphoma |
topic | Brief Definitive Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149217/ https://www.ncbi.nlm.nih.gov/pubmed/21788410 http://dx.doi.org/10.1084/jem.20101785 |
work_keys_str_mv | AT steiningeranne genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT mobsmarkus genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT ullmannreinhard genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT kochertkarl genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT kreherstephan genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT lamprechtbjorn genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT anagnostopoulosioannis genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT hummelmichael genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT richterjulia genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT beyermarc genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT janzmartin genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT klemkeclausdetlev genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT steinharald genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT dorkenbernd genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT sterrywolfram genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT schrockevelin genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT mathasstephan genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma AT assafchalid genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma |